

Executive re-structure across global operations

Announcement

PYC Therapeutics, (ASX: PYC) ('The Company' or 'PYC'), a precision medicine company developing new treatments for severe unmet patient needs, today announces a re-structuring of the Company's executive team. Dr. Rohan Hockings, previously the Managing Director of the Company's Australian operations will resume the role of Chief Executive Officer of PYC and Douglas Huey, previously the Chief Executive Officer of PYC will assume the role of Managing Director of PYC's US operations (PYC Therapeutics LLC).

The re-structure aligns to the recent strengthening of the Australian management team with the appointment of Professor Sue Fletcher to the role of Chief Scientific Officer to join Dr. Hockings and Chief Business Officer, Kaggen Ausma, in the Company's Australian operations. PYC will continue to build both clinical and commercialisation capabilities in the US in support of PYC's lead drug program and a growing pipeline of high impact precision therapeutics.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

ENDS For further information, please contact:

INVESTORS

Kaggen Ausma
CBO
info@pyctx.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0994

pyctx.com

PYC Therapeutics Limited

ACN 098 391 961